This paper explores the development, pharmacodynamic properties, uses and effects of the antiangiogenesis drugs. The idea started with Dr. Folkman, in 1961; and in 2004 Bevacizumab (Avastin) became the first antiangiogenesis drug to receive FDA approval (Katzung, Masters, & Trevor, 2009). Angiogenesis plays an important role in the growth and spread of cancer because, as cancer grows, it needs its own blood supply to receive oxygen and nutrients. Pro- Angiogenesis and antiangiogenesis factors are discussed. FDA-approved antiangiogenesis therapies could be comprised in 4 categories: 1) monoclonal antibodies, 2) tyrosine kinase inhibitors, 3) inhibitors of mTOR (mammalian target of rapamycin), and 4) other approved antiangiogenesis agents (Angiogenesis Foundation, 2009). They make a total of ten antiangiogenesis drugs, which are briefly discussed first as a group (advantages, limitations), and then individually (mechanism of action, pharmacological uses, and warnings).
Keywords: Antiangiogenesis, angiogenesis inhibitors, cancer treatment.
Current Use and Development of Antiangiogenesis Drugs as Adjuvant Therapy in Cancer Treatment.
Cancer is a leading cause of death and source of morbidity around the world, which incidence increases markedly with advancing age. Over the past 30 years, intensive research has lead to a significantly enhanced knowledge of this complex and frightening disease. We now know that genetics, environment, and behavior interact to modify both the risk of developing cancer, and the response to treatment. Novel therapies, based on our better understanding of the pathophysiology of cancer, have been added to improve the treatment strategies (McCance & Huether, 2006). Antiangiogenesis drugs, also called angiogenesis inhibitors, are part of this novel therapeutic approaches that increase the number of effective options available to fight these disorders, collectively called cancer.
